EMEA-002750-PIP01-19 - paediatric investigation plan

surufatinib

Key facts

• Active Substance:
  surufatinib
• Therapeutic area:
  Oncology
• Decision number:
  P/0142/2021
• PIP number:
  EMEA-002750-PIP01-19
• Pharmaceutical form(s):
  • Capsule (hard)
  • Powder for oral suspension
• Condition(s) / indication(s):
  • Treatment of all conditions included in the category of malignant neoplasms (except central nervous system tumours, haematopoietic and lymphoid tissue neoplasms)
  • Treatment of malignant neoplasms of haematopoietic and lymphoid tissue
• Route(s) of administration:
  Oral use
• Contact for public enquiries:

  Hutchison MediPharma Ltd

  E-mail: [e-mail]; Tel: [phone]

• Decision type:
  P: decision agreeing on a investigation plan, with or without partial waiver(s) and or deferral(s)
• Decision date:
  14/04/2021

Decision

P/0142/2021: EMA decision of 14 April 2021 on the agreement of a paediatric investigation plan and on the granting of a deferral for surufatinib (EMEA-002750-PIP01-19)

AdoptedReference Number: EMA/151840/2021